The Case CCC is committed to the clinical development of novel concepts through early phase clinical investigation. A long track record of successful translation of 'home-grown'scientific concepts has been facilitated by Protocol Specific Research Support (PSRS), and we continue our focus on investigator initiated, innovative, feasibility and Phase 1 clinical research protocols that contain laboratory correlates to advance the science of therapeutic discovery. PSRS is overseen by the Case CCC Clinical Research Office (CRO), which coordinates the activities of the Clinical Trials Core Facility (CTCF), Protocol Review and Monitoring Committee (PRMC), Data and Safety Monitoring, and Protocol Specific Research Support. The Case CCC has a robust infrastructure for early drug development, with consortium member institutional support in addition to a U01 (Dowlati, PI 5U01CA062502-18, Phase I Emphasis) grant and a NOI (Villalona, Consortium Pl, HHSN261201100070C, Phase 11 Emphasis) NIH contract. Further infrastructure support is enabled by the Case Western Reserve University Clinical Translational Research Collaborative (Davis, Pl 5UL1RR024989-05, CTSC), which provides additional expertise in drug development. While PSRS support explicitly does not overlap with these funding mechanisms, we are able to build upon the extensive local expertise in early phase clinical research in the design and conduct of Cancer Center studies eligible for PSRS. PSRS is limited to support of research nurses and data managers, and therefore leverages other institutional resources. A formalized process for award of PSRS funding begins with the submission of a 2 page letter of intent (LOI) and budget by principal investigators seeking PSRS for a particular study. This LOI undergoes structured evaluation by a Case CCC clinical research leadership committee with a determination of approval/disapproval. PSRS funds are disbursed based on protocol accrual, with per-patient reimbursement at rates determined at the time of approval of the application. Trials must be approved and prioritized by PRMC before any funds are distributed. To permit rapid real-time decision making, PSRS applications are accepted on a rolling basis. In the prior grant cycle, 431 patients were accrued to studies selected for PSRS.

Public Health Relevance

The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30CA043703-24
Application #
8765404
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
24
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Zhao, S; Sedwick, D; Wang, Z (2015) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 34:3885-94
Brubaker, Douglas; Difeo, Analisa; Chen, Yanwen et al. (2014) Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pac Symp Biocomput :125-35
Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14
Dabir, Snehal; Kluge, Amy; McColl, Karen et al. (2014) PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134:1045-54
Yori, Jennifer L; Lozada, Kristen L; Seachrist, Darcie D et al. (2014) Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res 74:4762-71
Sizemore, Gina M; Sizemore, Steven T; Seachrist, Darcie D et al. (2014) GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem 289:24102-13
Zapanta Rinonos, Serendipity; Rai, Urvashi; Vereb, Sydney et al. (2014) Sequential logic of polarity determination during the haploid-to-diploid transition in Saccharomyces cerevisiae. Eukaryot Cell 13:1393-402
Dotan, Efrat; Devarajan, Karthik; D'Silva, A James et al. (2014) Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 13:192-8
Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao et al. (2014) Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J 28:2260-71
Dabir, Snehal; Babakoohi, Shahab; Kluge, Amy et al. (2014) RET mutation and expression in small-cell lung cancer. J Thorac Oncol 9:1316-23

Showing the most recent 10 out of 975 publications